SCHEMBL23217460

SCHEMBL23217460

NCc1cccc(-c2cc(COc3cc(CN)ccc3CC(=O)O)cc3c(C(F)(F)F)coc23)c1

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CFD P00746 15/20 0.53
F11 P03951 3/20 0.51
KLKB1 P03952 2/20 0.51
TPSB2 P20231 2/20 0.51
PLG P00747 1/20 0.51
PLAU P00749 1/20 0.51
F7 P08709 1/20 0.51
NR1H2 P55055 2/20 0.42
NR1H3 Q13133 2/20 0.42
PTGER1 P34995 1/20 0.41
PTGER4 P35408 1/20 0.41
PTGER3 P43115 1/20 0.41
PTGER2 P43116 1/20 0.41
PPARG P37231 1/20 0.39
PPARD Q03181 1/20 0.39
PPARA Q07869 1/20 0.39
RXRA P19793 1/20 0.38
RXRB P28702 1/20 0.38
RXRG P48443 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30010183 1.00 CFD (0.53) CFDF11KLKB1TPSB2PLG
SCHEMBL21455493 0.97 CFD (0.50) CFDF11KLKB1TPSB2PLG
SCHEMBL21438277 0.94 CFD (0.51) CFDF11KLKB1TPSB2PLG
SCHEMBL21438262 0.94 CFD (0.51) CFDF11KLKB1TPSB2PLG
SCHEMBL21438778 0.93 CFD (0.61) CFDF11KLKB1TPSB2PLG
SCHEMBL21437792 0.92 CFD (0.53) CFDF11KLKB1TPSB2PLG
SCHEMBL21437778 0.92 CFD (0.49) CFDF11KLKB1TPSB2PLG
SCHEMBL30010599 0.90 CFD (0.45) CFDF11KLKB1TPSB2PLG
SCHEMBL23217770 0.90 CFD (0.45) CFDF11KLKB1TPSB2PLG
SCHEMBL21439077 0.89 CFD (0.57) CFDF11KLKB1TPSB2PLG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250275991-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-09-04 US disclosed
CN-114555570-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-27 CN disclosed
WO-2021072156-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed
WO-2021072156-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250275991-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB CFD 1/4885F11 15/4885KLKB1 64/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.